Article
Immunology
Ryan K. Shields, David L. Paterson, Pranita D. Tamma
Summary: Acinetobacter baumannii-calcoaceticus complex is a common cause of nosocomial infections with high antibiotic resistance. Traditional combination therapy includes colistin, sulbactam, and tetracyclines. New beta-lactam agents like cefiderocol and sulbactam-durlobactam have shown contrasting results in recent clinical trials. Effective treatment for CRAB infections requires a personalized approach considering host factors, site of infection, pharmacokinetic-pharmacodynamic principles, and local molecular epidemiology.
CLINICAL INFECTIOUS DISEASES
(2023)
Review
Infectious Diseases
Luigi Principe, Stefano Di Bella, Jacopo Conti, Mariagrazia Perilli, Alessandra Piccirilli, Cristina Mussini, Giuliana Decorti
Summary: This study reviewed the resistance of A. baumannii to sulbactam/durlobactam. The results showed that the resistance to sulbactam/durlobactam is limited, except for MBL-producing strains.
Article
Immunology
Jose Cedano, Michelle Baez, Fernando Pasteran, Sabrina Daiana Montana, Grace Ra, Venjaminne Fua, Alejandra Corso, Marcelo E. Tolmasky, Robert A. Bonomo, Maria Soledad Ramirez
Summary: This study tested the efficacy of the combination of sulbactam and a novel DBO, zidebactam, against carbapenem-resistant A. baumannii isolates. The results showed that the sulbactam/zidebactam combination was able to restore sulbactam susceptibility in resistant isolates, including those resistant to the sulbactam/avibactam combination.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Immunology
Dimitra Petropoulou, Maria Siopi, Sophia Vourli, Spyros Pournaras
Summary: This study evaluated the in vitro activity of the sulbactam-durlobactam (SD) combination against carbapenem-resistant A. baumannii isolates. SD demonstrated the lowest minimum inhibitory concentration (MIC90) and showed potential utility for the treatment of infections caused by A. baumannii. The addition of imipenem further enhanced the activity of SD.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Review
Pharmacology & Pharmacy
Benjamin August, Andrew Matlob, Pramodini B. Kale-Pradhan
Summary: The pharmacology, efficacy, and safety of intravenous sulbactam-durlobactam (SUL-DUR) in treating carbapenem-resistant Acinetobacter baumannii (CRAB) infections were reviewed. SUL-DUR has shown to be highly effective in treating pneumonia caused by CRAB. However, further research is needed to examine the impact of combining sulbactam-durlobactam with other active antimicrobials on clinical trial results.
ANNALS OF PHARMACOTHERAPY
(2023)
Article
Immunology
Dana J. Holger, Ashlan J. Kunz Coyne, Jing J. Zhao, Avnish Sandhu, Hossein Salimnia, Michael J. Rybak
Summary: This study reports a case of a critically ill patient with extensively drug-resistant Acinetobacter baumannii necrotizing pneumonia complicated by empyema in Detroit, Michigan. A precision medicine approach was used to guide the rational combination antimicrobial therapy through whole-genome sequencing, susceptibility testing, and synergy analysis.
OPEN FORUM INFECTIOUS DISEASES
(2022)
Article
Infectious Diseases
Bernardetta Segatore, Alessandra Piccirilli, Sabrina Cherubini, Luigi Principe, Giovanni Alloggia, Maria Lina Mezzatesta, Mario Salmeri, Stefano Di Bella, Roberta Migliavacca, Aurora Piazza, Elisa Meroni, Paolo Fazii, Daniela Visaggio, Paolo Visca, Venere Cortazzo, Giulia De Angelis, Arianna Pompilio, Mariagrazia Perilli
Summary: The in vitro activity of the sulbactam-durlobactam (SUL-DUR) combination was evaluated against carbapenem-resistant A. baumannii (CRAb) clinical strains collected from multiple regions in Italy. The combination showed effectiveness against most isolates, with only a few exhibiting resistance due to the presence of additional resistance genes and mutations. The isolates also showed the presence of multidrug efflux pump genes associated with multidrug resistance.
Article
Infectious Diseases
Jacqueline Findlay, Laurent Poirel, Maxime Bouvier, Patrice Nordmann
Summary: This study investigated the resistance mechanisms of carbapenemase-producing Acinetobacter baumannii and evaluated the in vitro antibacterial activity of sulbactam combined with durlobactam. The results showed that sulbactam-durlobactam had excellent activity against A. baumannii isolates and identified potential mechanisms involved in resistance, including PBP substitutions and specific beta-lactamase production.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2022)
Review
Pharmacology & Pharmacy
Amer El-Ghali, Ashlan Kunz J. Coyne, Kaylee Caniff, Callan Bleick, Michael J. Rybak
Summary: SUL-DUR is a novel beta-lactam-beta-lactamase inhibitor designed for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) infections. The FDA's fast-track approval for SUL-DUR is pending after the completion of the phase III ATTACK trial, which showed that SUL-DUR was non-inferior to colistin with a better safety profile. With limited treatment options available, SUL-DUR holds promise for the treatment of CRAB infections.
Article
Microbiology
Samir H. Moussa, Adam B. Shapiro, Sarah M. Mcleod, Ramkumar Iyer, Nicole M. Carter, Yu-Kuo Tsai, L. Kristopher Siu, Alita A. Miller
Summary: Acinetobacter baumannii-calcoaceticus complex (ABC) causes severe infections that are difficult to treat, but sulbactam-durlobactam is an effective antibiotic for treating these infections. A global surveillance study showed that a small percentage of ABC isolates have developed resistance to this antibiotic, with metallo-beta-lactamases or penicillin-binding protein 3 mutations being the main driving factors.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Infectious Diseases
Fernando Pasteran, Jose Cedano, Michelle Baez, Ezequiel Albornoz, Melina Rapoport, Jose Osteria, Sabrina Montana, Casin Le, Grace Ra, Robert A. Bonomo, Marcelo E. Tolmasky, Mark Adams, Alejandra Corso, Maria Soledad Ramirez
Summary: The study focuses on testing different combinations of sulbactam with beta-lactamase inhibitors to treat multi-drug resistant Acinetobacter clinical isolates. Results show that sulbactam combined with avibactam or relebactam can restore sulbactam activity against the isolates, offering new options for treating infections caused by widespread oxacillinases and metallo-beta-lactamases producers.
Article
Biochemistry & Molecular Biology
Manigandan Krishnan, Joonhyeok Choi, Ahjin Jang, Young Kyung Yoon, Yangmee Kim
Summary: Developed peptide R-Pro9-3D shows rapid and effective antibacterial activity against CRAB, damaging its outer membrane with lower cytotoxicity and better proteolytic stability. It can also reduce LPS-induced inflammation and lessen organ damage in a mouse model of CRAB-induced sepsis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Infectious Diseases
Xingchen Bian, Xiaofen Liu, Meiqing Feng, Phillip J. Bergen, Jian Li, Yuancheng Chen, Huajun Zheng, Sichao Song, Jing Zhang
Summary: This study conducted whole genome sequencing on carbapenem-resistant Acinetobacter baumannii isolates and investigated the bacterial killing effects of colistin and sulbactam combination therapy. The results showed that higher sulbactam concentration and longer infusion time substantially enhanced bacterial killing in a dynamic model.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2021)
Article
Microbiology
Carina Mueller, Sandra Reuter, Julia Wille, Kyriaki Xanthopoulou, Danuta Stefanik, Hajo Grundmann, Paul G. Higgins, Harald Seifert
Summary: This study conducted molecular epidemiology and global distribution research on 313 carbapenem-resistant Acinetobacter baumannii isolated from 114 study centers in 47 countries. The results revealed a wide variation in the distribution of carbapenemase encoding genes among different geographical regions.
Article
Immunology
Mollie VanNatta, Laurie Grier, Muhammad H. Khan, Paulette Pinargote Cornejo, Mohammad Alam, Samir H. Moussa, Jennifer G. Smith, Samuel L. Aitken, Alexandre E. Malek
Summary: The treatment of carbapenem-resistant Acinetobacter baumannii infection with emerging cefiderocol resistance remains challenging. This study presented a case of in vivo emergence of pandrug-resistant A baumannii that was successfully treated with investigational sulbactam-durlobactam-based antibiotic regimen. Longitudinal genomic analysis showed the development of resistance and genetic mutations over time.
OPEN FORUM INFECTIOUS DISEASES
(2023)
